about
Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal diseaseThe pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder diseaseLongitudinal trends and subgroup analysis in publication patterns for preclinical data of newly approved drugs.Pitfalls in the normalization of real-time polymerase chain reaction data.An anthology from Naunyn-Schmiedeberg's Archives of Pharmacology.Are "functionally related polymorphisms" of renin-angiotensin-aldosterone system gene polymorphisms associated with hypertension?A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Apoptosis induction by doxazosin and other quinazoline alpha1-adrenoceptor antagonists: a new mechanism for cancer treatment?Emerging country pharmacology: a 10-year perspective from Naunyn-Schmiedeberg's Archives of Pharmacology.Small and intermediate conductance Ca(2+)-activated K+ channels confer distinctive patterns of distribution in human tissues and differential cellular localisation in the colon and corpus cavernosum.A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis.Association of hypertension with symptoms of benign prostatic hyperplasia.Comparison of problem-and lecture-based pharmacology teaching.EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study.The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum.Ex Vivo Characterization of a Novel Iodine-123-Labelled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D2/3 Receptors.Pharmacogenetics of hypertension treatment: a structured review.β3-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinaseTreatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system.Role of muscarinic receptor antagonists in urgency and nocturia.How valid are animal models to evaluate treatments for pulmonary hypertension?Tools to study beta3-adrenoceptors.Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based?Epac and the cardiovascular system.Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptorsManaging the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.β-Adrenoceptor-mediated Relaxation of Urinary Bladder Muscle in β2-Adrenoceptor Knockout Mice.Pharmacologic treatment of male stress urinary incontinence: systematic review of the literature and levels of evidence.Cholinergic innervation and muscarinic receptors in the human prostate.Regulation of G protein-coupled receptor signalling: focus on the cardiovascular system and regulator of G protein signalling proteins.Similarities and differences in the autonomic control of airway and urinary bladder smooth muscleDrug-induced urinary incontinence.Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence.Basic mechanisms of urgency: preclinical and clinical evidence.Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target.Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
P50
Q26748814-C8D2E9EA-715C-4E4F-B83B-36E81B83C555Q26864937-23F963F2-7106-47D2-93C3-667CA4B997A4Q31028700-99F6476B-D74D-4F1C-9F8D-BECCCC1DEB9EQ31106076-A576E9FF-8F0B-4840-B678-B8FDBCF8091EQ33237424-B3561BFB-77CA-432A-824E-B56C757B6474Q33594915-D7962262-EDE1-4FC9-97A7-D467AA6301BDQ33605906-7239DB0A-22B7-45D6-96B6-4DA386262FC1Q33746215-7E85852A-3FC6-4EDD-A6CD-FF3BA3AB1138Q33927642-78692D1D-7388-45C6-A8D3-993721313245Q34318771-B6538C31-AAF4-4E76-B1D5-F7AEEB922B8FQ34354873-842099F1-A35B-43BD-9F78-D52FAD941C0AQ34550928-15F08CFF-49A2-422C-BD07-C1FCC4344AC0Q34586898-BDFBC7D3-BFB1-4723-889A-E7F9DA7075C1Q34642314-C74BDCF1-1A14-4985-B410-E4077A68F345Q34709479-EA6CE976-A7F7-486B-938E-0FF0013CACF2Q34709612-E65C8FEB-5641-4773-AB34-DF0B9261F625Q34918396-B1BB3842-C276-435A-81C5-7AABA3841716Q35596839-E77F6D69-B829-4627-BDED-64E0C3C88EA3Q35762174-B65CC2A1-51DA-4EBF-9B56-60098483FAB5Q36116539-CBD36041-06C2-403C-AE75-6CDD75A2FF3CQ36219834-6FDA4AFC-7B6E-43B7-AD31-F20857C91F15Q36577620-8917B8C0-126A-4286-9DEE-A4A69A489157Q36702797-BAE68EB8-26E3-4F92-815E-5399A23439C0Q36711600-30A77C04-AE43-429B-95C0-FD5A2EB9F537Q36727634-173A02DD-CF22-4C4B-ADDC-0CAC3E2AB530Q36784801-2B401916-90FC-449D-9969-DCDEEB4A926EQ36872815-303B49BD-4003-4B6F-8482-6099D7AC2B2CQ36881512-6D148EFA-9720-483C-A5CC-518E028F17A1Q36962762-A17795E7-EBB5-452A-9348-7C65D249D48CQ37045325-C29DD861-0DD3-4CC7-8C6C-C5B23EFE923CQ37138158-9DF94DF6-3E1E-49D7-B20A-F634109B924BQ37189382-5C161FBB-CA21-4344-BD2E-F9ACEE4FD27BQ37200816-7C08E875-C478-4278-917F-D5A9570EC423Q37226537-2C73FB38-46F1-4CE9-84F3-511DDE31EEB8Q37341473-9A9F7559-E85A-465B-A0E1-407A88F8F241Q37485861-FFBE5E5C-88FB-4F77-9905-23848D384436Q37518171-8F9B2118-F201-45D6-932F-925DD9FB1F70Q37869049-7F19FDCE-DBED-45BC-90B4-A4479A2999AFQ38065991-2C6AB66B-1ADE-4819-A68C-70CEBE8D6388Q38088977-1CA4FB0E-D0BC-4957-8F26-686D20ACAB76
P50
description
reasearcher, member of Academia Europaea
@en
name
Martin C. Michel
@ast
Martin C. Michel
@en
Martin C. Michel
@es
Martin C. Michel
@nl
type
label
Martin C. Michel
@ast
Martin C. Michel
@en
Martin C. Michel
@es
Martin C. Michel
@nl
prefLabel
Martin C. Michel
@ast
Martin C. Michel
@en
Martin C. Michel
@es
Martin C. Michel
@nl
P31
P5463
Michel_Martin